Lead drug receives new patent protection through 2027
New Patents Issued to Diffusion Pharmaceuticals
Diffusion Pharmaceuticals LLCMedia:David G. Kalergis, MBA/JDCEO434-220-0718orGBM Study Information:Kim Whitten, Pharm.D,Vice President, Drug Development434-220-0718
Diffusion Pharmaceuticals LLC, a biotechnology company focused on innovative cancer treatments, today announced that the U.S. Patent and Trademark Office has granted it patent numbers 7919527 and 8030350, entitled “Bipolar Trans Carotenoids Salts and Their Uses” and “Trans Carotenoids, Their Synthesis and Uses,” respectively. These patents include compound, composition, and methods of use relating to Diffusion's lead molecule, (TSC), as well as the entire family of first-in-class new chemical entities in the Company’s pipeline of therapeutic candidates. Diffusion Pharmaceuticals is commercializing this family of first-in-class drugs to treat serious or life-threatening medical conditions characterized by hypoxia or oxygen deprivation at the cellular level. Enrollment is currently underway in a multi-center Phase I/II study of TSC for the improved treatment of newly diagnosed primary brain cancer patients.
“These new patents are important additions to our intellectual property portfolio, providing strong protection through at least 2027,” said David G. Kalergis, Diffusion’s CEO.
Currently the Company has 7 issued U.S. patents, 10 issued foreign patents and more than 70 pending patent applications filed in all major international markets.
Trans sodium crocetinate (TSC) is a proprietary, first-in-class oxygen diffusion enhancing compound formulated for IV delivery. Based on a novel mechanism of action, TSC safely re-oxygenates hypoxic tissue without causing hyper-oxygenation of normal tissue. Published studies demonstrate a tripling of survival and superior tumor control when TSC is combined with radiation and chemotherapy in animal models of primary brain cancer.
Diffusion Pharmaceuticals is a clinical-stage company developing first-in-class drugs which target the numerous unmet medical needs characterized by oxygen deprivation (hypoxia) at the cellular level. These proprietary small molecules work by a novel mechanism of action that enhances the diffusion of oxygen selectively to hypoxic tissue. Potential breakthrough clinical applications include oncology, cardiovascular diseases, stroke and respiratory disorders. Diffusion’s lead program is the use of TSC in the treatment of solid cancerous tumors. A phase I/II clinical study of TSC dosed concomitantly with radiation and chemotherapy in newly diagnosed GBM patients is currently enrolling patients. Diffusion Pharmaceuticals, which is privately held, is located in Charlottesville, Virginia. For more information, visit .